Fig. 4From: A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinomaKaplan–Meier analyses of LUAD patients with stage, KRAS mutation status, and EGFR mutation status, including a stage 3–4, b stage 1–2, c KRAS mutation, d KRAS wild-type, e EGFR mutation, and f EGFR wild-typeBack to article page